Genmab - ADR
GMAB
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
74.4% downsideOvervalued by 74.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $15.40 Billion |
|---|---|
| Enterprise Value | $19.25 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.55 |
| Beta | 0.68 |
| Outstanding Shares | 613,836,700 |
Return
| Return on Equity | 17.37% |
|---|---|
| Return on Assets | 7.98% |
| Return on Invested Capital | 24.00% |
Valuation & Multiples
| P/E Ratio | 18.75 |
|---|---|
| PEG | -25.79 |
| Price to Sales | 1.67 |
| Price to Book Ratio | 2.79 |
| Enterprise Value to Revenue | 2.01 |
| Enterprise Value to EBIT | 7.16 |
| Enterprise Value to Net Income | 19 |
| Total Debt to Enterprise | 0.28 |
| Debt to Equity | 0.95 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0261▼ 60.91% |
|---|---|
| Total Calls | 413,400▲ 406.00% |
| Total Puts | 10,800▼ 79.19% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 13.28%▲ 1.39% |
|---|---|
| Total Invested | $2.23B▼ 1.01% |
| Investors Holding | 276▼ 19.00% |
ESG Score
No data
About Genmab
CEO: Jan van de Winkel Relevant Senate Committees
Controls taxation, trade, and entitlement spending (like Medicare). Decisions on corporate tax policy, drug pricing within Medicare, and international trade agreements directly impact Genmab's profitability, market access, and overall valuation.
Allocates discretionary federal spending, directly determining funding levels for agencies like NIH (critical for research) and healthcare programs (e.g., Medicare/Medicaid) that can impact the market for biotechnology products developed by Genmab.
Directly regulates the FDA (critical for drug approval) and NIH (key for research funding), and significantly influences labor laws and healthcare policy, all of which directly impact the performance of biotechnology firms like Genmab.
Oversees intellectual property laws (patents, which are vital for biotech R&D), antitrust enforcement (influencing mergers and market competition), and other legal frameworks directly impacting Genmab's core business model and strategic decisions.